^
Association details:
| Biomarker: | MSI-H/dMMR + POLE mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors
Published date:
11/01/2023
Excerpt:
Patients received 500 mg of dostarlimab intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, discontinuation, or withdrawal...Three of 6 patients with MMRp/POLE-altered tumors achieved a response (including 1 patient with CRC who achieved a CR)...
DOI:
10.1001/jamanetworkopen.2023.41165
Trial ID:
Source:
Title:
Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study
Published date:
05/26/2022
Excerpt:
For this third interim analysis, 153 pts with dMMR/MSI-H EC and 210 pts with dMMR/MSI-H/POLε-mut non-EC solid tumors (56% colorectal cancer, 11% gastric) were enrolled and treated. Efficacy analysis was performed for 143 dMMR/MSI-H EC and 204 dMMR/MSI-H/POLε-mut non-EC pts who had measurable disease at baseline and ≥6 mo of follow-up. ORRs were 45.5% (dMMR/MSI-H EC) and 43.1% (dMMR/POLε-mut non-EC solid tumors; Table). Probability of PFS at 6, 9, and 12 mo was 49.5%, 48.0%, and 46.4% in dMMR/MSI-H EC and 51.8%, 48.1%, and 46.4% in dMMR/MSI-H/POLε-mut non-EC. Median (m) DOR and mOS were not reached for either cohort. Dostarlimab demonstrated durable antitumor activity across 16 tumor types in pts with dMMR solid tumors...
DOI:
10.1200/JCO.2022.40.16_suppl.2587
Trial ID:
